Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Quest Diagnostics Incorporated (DGX) — XLV Health Care · S&P 500 Profile |奎斯特診斷介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Quest Diagnostics Incorporated (DGX) — Business, History & S&P 500 Profile |奎斯特診斷介紹

Quest Diagnostics company profile · diagnostic testing & information services (labs, patients, physicians) · history · financial snapshot · S&P 500 rank #342 · 奎斯特診斷公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 2, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$27.77B
Nov 2, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.04%
Rank #342 · Nov 2, 2026 (Slickcharts)
SECTOR RANK
#45
Health Care · Nov 2, 2026
S&P 500 RANK
#342
0.04% · Nov 2, 2026

SNAPSHOT

TickerDGX (NYSE)
CompanyQuest Diagnostics Incorporated
GICS sector / industryHealth Care (XLV) / Health Care Services
S&P 500 rank (by weight)#342 · 0.04% (Nov 2, 2026)
Sector rank (by market cap)#45 in Health Care (Nov 2, 2026)
Share price (frozen benchmark)$251.63 (Nov 2, 2026)
HeadquartersSecaucus, New Jersey
Founded1967 (as Metropolitan Pathology Laboratory)
CEOJim Davis (Chairman, President and CEO)
Employeesabout 55,000 (2025 profile)
Market cap$27.77B (Nov 2, 2026)

WHAT IT DOES

Quest Diagnostics is one of the world's largest providers of diagnostic testing and information services, running laboratories and patient service centers that test blood, urine and other samples for physicians, hospitals, employers and patients, and selling the resulting data and insights.

The model is the standard national-laboratory model: routine volume plus specialty menu, with acquisitions folding regional laboratories into the national network. FY2025 net revenues were $11,035M, up 11.8% from $9,872M, GAAP operating income was $1,556M (up 15.6% from $1,346M), adjusted operating income was $1,759M at a 15.9% margin, net income attributable was $992M, reported diluted EPS was $8.75 (up 13.8%) and adjusted diluted EPS was $9.85 (up 10.3%), with cash from operations of $1.89B.

TradingKey's $988M net-income figure is the same line rounded differently — the company-release $992M is used.

BUSINESS SEGMENTS — FY2025

SegmentRevenueShareYoY
Diagnostic Information Services———
Diagnostic Solutions and other———

Quest's business is overwhelmingly diagnostic information services — the laboratory network itself — with diagnostic solutions and other services (including employer testing and data products) as a smaller complement. The segment table is qualitative because a revenue split is not stated in the sources used.

HISTORY

YearMilestone
1967Metropolitan Pathology Laboratory founded
1996Quest Diagnostics spins off from Corning
2020Testing scales up sharply during the COVID-19 pandemic
2025FY2025 net revenues reach $11,035M, up 11.8%

COMPETITIVE POSITION

  • Scale — one of two national laboratory networks in the U.S.
  • Acquisitions — regional laboratories fold into the national network.
  • Specialty menu — advanced diagnostics carry higher prices.
  • Payer pressure — insurers and Medicare set prices for much of the volume.
  • Competition — the other national laboratory network and hospital in-house laboratories contest the same volumes.

FINANCIAL SNAPSHOT — FY2025

Net revenues$11,035M (+11.8% YoY)
GAAP operating income$1,556M (+15.6% YoY)
Adjusted operating income (stated separately)$1,759M (15.9% margin)
Net income attributable / Reported diluted EPS$992M / $8.75 (adjusted EPS $9.85)
Cash from operations$1.89B
Source: Quest Diagnostics FY2025 release (Feb 10, 2026). GAAP and adjusted figures are stated separately. TradingKey's $988M is the same net-income line rounded differently; the company-release $992M is used.

KEY RISKS

  • Reimbursement — payer fee schedules can cut prices on routine tests.
  • Test volumes — physician visit trends set demand.
  • Acquisitions — deals must earn their price.
  • Labor costs — technologists are hard to staff.

WHY IT MATTERS FOR THE S&P 500

Quest Diagnostics is the S&P 500's other diagnostics name: at a 0.04% index weight and #45 in Health Care by market cap, it is, with the other national laboratory network, the index's exposure to laboratory testing volumes.

Its test volumes are a standing read on U.S. healthcare utilization — requisition counts move before claims data does.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 close) and Slickcharts S&P 500 analysis page (market cap)
FinancialsQuest Diagnostics FY2025 results, release dated Feb 10, 2026 (fiscal year ended Dec 31, 2025), company profile sources
Sector classificationGICS (Health Care Services) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.

FINANCIALS

繁體中文版

公司快照

代碼DGX(NYSE)
公司Quest Diagnostics Incorporated
GICS 板塊/行業醫療保健(XLV)/醫療保健服務
標普500排名(按權重)#342 · 0.04%(2026 年 11 月 2 日)
板塊內排名(按市值)醫療保健第 #45(2026 年 11 月 2 日)
股價(凍結基準)$251.63(2026 年 11 月 2 日)
總部美國新澤西州錫考克斯
成立1967 年(前身為 Metropolitan Pathology Laboratory)
行政總裁Jim Davis(董事長、總裁兼行政總裁)
員工約 55,000(2025 年簡介)
市值$27.77B(2026 年 11 月 2 日)

業務概覽

奎斯特診斷是全球最大的診斷檢測與資訊服務商之一,營運實驗室與病人服務中心,為醫生、醫院、僱主與病人檢測血液、尿液及其他樣本,並銷售所得數據與見解。

其模式為標準全國實驗室模式:常規銷量加專科項目,收購將地區實驗室併入全國網絡。FY2025 淨收入為 $11,035M,同比增長 11.8%(FY2024 為 $9,872M),GAAP 營業利潤為 $1,556M(同比 +15.6%,上年為 $1,346M),經調整營業利潤為 $1,759M(利潤率 15.9%),歸屬淨利潤為 $992M,申報攤薄每股收益為 $8.75(同比 +13.8%),經調整攤薄每股收益為 $9.85(同比 +10.3%),營運現金為 $1.89B。

TradingKey 報淨利潤 $988M 為同一口徑的不同四捨五入——此處用公司公告 $992M。

業務板塊 — FY2025

板塊收入佔比同比
診斷資訊服務———
診斷解決方案及其他———

奎斯特業務絕大部分為診斷資訊服務——即實驗室網絡本身——診斷解決方案及其他服務(包括僱主檢測與數據產品)為較小的補充。板塊收入拆分未見於所用來源,故板塊表只作定性列示。

歷史沿革

年份里程碑
1967Metropolitan Pathology Laboratory 創立
1996奎斯特診斷自康寧分拆
2020新冠疫情期間檢測大幅擴大
2025FY2025 淨收入達 $11,035M,同比增長 11.8%

競爭地位

  • 規模——美國兩大全國實驗室網絡之一。
  • 收購——地區實驗室併入全國網絡。
  • 專科項目——先進診斷價格較高。
  • 付款方壓力——保險商與聯邦醫療保險為大部分銷量定價。
  • 競爭——另一全國實驗室網絡與醫院內部實驗室爭奪同一批銷量。

財務快照 — FY2025

淨收入$11,035M(同比 +11.8%)
GAAP 營業利潤$1,556M(同比 +15.6%)
經調整營業利潤(分開列示)$1,759M(利潤率 15.9%)
歸屬淨利潤/申報攤薄每股收益$992M/$8.75(經調整每股收益 $9.85)
營運現金$1.89B
來源:奎斯特診斷 FY2025 公告(2026 年 2 月 10 日)。GAAP 與經調整數字分開列示。TradingKey 報 $988M 為同一淨利潤口徑的不同四捨五入;此處用公司公告 $992M。

主要風險

  • 報銷——付款方收費表可削減常規檢測價格。
  • 檢測銷量——醫生就診趨勢決定需求。
  • 收購——交易必須賺回其價格。
  • 勞工成本——技術員難以招聘。

對標普500的重要性

奎斯特診斷是標普500的另一診斷標的:指數權重 0.04%、醫療保健板塊市值第 #45,與另一全國實驗室網絡同為指數對實驗室檢測銷量的敞口。

其檢測銷量,是美國醫療使用量的常設讀數——檢測申請數往往先於理賠數據變動。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日收盤)及 Slickcharts 標普500分析頁(市值)
財務奎斯特診斷 FY2025 業績,2026 年 2 月 10 日公告(財政年度截至 2025 年 12 月 31 日)、公司簡介來源
板塊分類GICS(醫療保健服務),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · DGX
Data as of Nov 2, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · VeriSign, Inc. (VRSN) — XLK Information Technology · S&P 500 Profile |威瑞信介紹Next · Jabil Inc. (JBL) — XLK Information Technology · S&P 500 Profile |捷普介紹

Entered 2026-11-03 13:20 · updated 2026-11-14 23:17 · rev 5